Cardiovascular Clinical Trial
Official title:
A Phase I Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 Following Single and Multiple Ascending Doses in Participants With Dyslipidemia
A study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD1705 in participants with dyslipidemia.
This is a first time in human study in male and female (of non-childbearing potential) participants with dyslipidemia. The study consists of two parts: 1. Part A (single ascending dose): Part A of the study will include three parts: A1 for non-Asian participants, A2 for Japanese participants, and A3 for Chinese participants. Parts A2 and A3 are optional. 2. Part B (multiple ascending dose): Part B of the study will include three parts: B1 for non-Asian participants receiving moderate- or high-intensity statin therapy, B2 for Japanese participants not receiving statin therapy, and B3 for participants who are receiving moderate- or high-intensity statin therapy, with the additional diagnosis of type 2 diabetes (T2D), and with HbA1c < 7.5%. Parts B2 and B3 are optional. The study will comprise of: - A Screening Period of maximum 60 days for both Part A and Part B. - Part A: A single dose of AZD1705 with an in-clinic period of 3 days. - An outpatient Follow-up Period of approximately 16 weeks. - Part B: 2 doses of AZD1705, given 28 days apart with an in-clinic period. - An outpatient Follow-up Period of approximately 20 weeks. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03236363 -
Effectiveness of MOVI Interventions on Adiposity, Cognition and Motor Competence: MOVI-da10!
|
N/A | |
| Completed |
NCT03236337 -
Effectiveness of MOVI Interventions on Adiposity, Cognition and Subclinical Atherosclerosis: MOVI-daFit!
|
N/A | |
| Completed |
NCT01304641 -
Cardiovascular Events Based On Statin Initiation In The Elderly
|
||
| Terminated |
NCT03277183 -
Frequent, Low-Dose Erythropoietin A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin
|
Phase 4 | |
| Not yet recruiting |
NCT05316025 -
Cardiovascular Digital Health Data Observatory
|
||
| Completed |
NCT03170193 -
AMG 529 First in Human Study
|
Phase 1 | |
| Recruiting |
NCT05775484 -
Exercise to Slow Cardiovascular Ageing Progression
|
||
| Active, not recruiting |
NCT05085275 -
Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease
|
Phase 3 | |
| Active, not recruiting |
NCT04863040 -
The Impact of Activity Breaks on Cognitive Function, Adiposity and Fitness in Preschoolers
|
N/A | |
| Not yet recruiting |
NCT04866732 -
Physical Activity Program for Cardiac Health Among Older African American Populations
|
N/A | |
| Recruiting |
NCT05568966 -
Collection of Blood Samples for New Diagnostic Devices 2
|
N/A | |
| Recruiting |
NCT01820598 -
Phase II Study of Neuromuscular Electrical Multisite System on Cardiovascular Effects in Severe Obese Patients
|
N/A | |
| Completed |
NCT00824330 -
Home-Based Walking Study in Older Adults With Type 2 Diabetes
|
N/A | |
| Completed |
NCT00387452 -
Exercise and Cardiovascular Control During Upright Tilt in Older Adults With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT05249296 -
The Impact of Green Spaces on the General Well-being and Stress of Students
|
N/A | |
| Completed |
NCT01232309 -
Effects of Chitin-Glucan on Oxidized Low-Density Lipoprotein (LDL)
|
N/A | |
| Completed |
NCT01489696 -
A Study to Evaluate Cardiovascular Interactions Between Mirabegron and Tamsulosin
|
Phase 1 | |
| Completed |
NCT00954902 -
Effects of Antioxidants on Cardiovascular Risk Measures (Spice Study)
|
N/A | |
| Completed |
NCT04216238 -
Association of Wearable Activity Monitors With Post-Operative Activity Level Among Cardiovascular Surgical Patients
|
||
| Completed |
NCT04121416 -
Comparison of Effects of Oxycodone and Sufentanil on Cardiovascular Stress Induced by Tracheal Intubation in the Patients With Coronary Heart Disease Undergoing Major Noncardiac Surgery
|
N/A |